# A Study of BPI-452080 in Subjects With Solid Tumors

> **NCT05843305** · PHASE1 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 87 (estimated)

## Conditions studied

- Solid Tumor
- Renal Cell Carcinoma
- Von Hippel-Lindau Disease

## Interventions

- **DRUG:** BPI-452080

## Key facts

- **NCT ID:** NCT05843305
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-28
- **Primary completion:** 2025-03-25
- **Final completion:** 2025-10-31
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05843305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05843305, "A Study of BPI-452080 in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05843305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*